Archive — US — turtlesai
Perimeter Medical Imaging AI Updates Investors on Advances in OCT Technology andAI
Perimeter Medical Imaging AI's CEO, Adrian Mendes, will present advances in OCT technology and AI at the Life Sciences Virtual Investor Forum on June 12, 2025. The company highlights notable clinical success with the B-Series OCT device and will discuss the operational strategy and expansion opportunities, including partnerships and FDA-cleared imaging systems.
Key points
- Event on June 12, 2025, at 12:30 p.m. ET through a virtual forum.
- CEO Adrian Mendes will present the latest on OCTS-Series and B-Series advances.
- B-Series device demonstrated significant success in clinical trials, detecting residual disease in 40% of participants.
- Results from ASBrS 2025 trial included 88.1% margin accuracy with a p-value of 0.0050.
- S-Series is FDA-cleared for intraoperative cellular imaging, supporting surgical decision-making.
- Clinical partnerships are expanding, with recent developments in New Mexico and Tennessee.
- Presentation recording will be available for 90 days, encouraging ongoing communication with investors.
Why it matters
- The move towards advanced imaging technologies in healthcare aligns with current trends emphasizing AI integration.
- Perimeter's development reflects growing investment and interest in precision medicine and surgical tools.
- The Cancer Prevention and Research Institute of Texas backing signifies a broader trend in increasing funding for innovative medical technologies.
The upcoming presentation on June 12 marks a key moment for Perimeter Medical Imaging AI, aiming to solidify its position in the competitive landscape of intraoperative imaging and AI technology, while ensuring transparent communication with its investors.